研究单位：[1]Henan Cancer Hospital[2]Chongqing Peg-Bio Biopharm Co., Ltd.[3]Affiliated Hospital of Hebei University,Baoding,Hebei,China,071000[4]The First Affiliated Hospital of Henan University of Science and Technology,Luoyang,Henan,China,471003[5]Henan Cancer Hospital,Zhengzhou,Henan,China,450008[6]Yiyang Central Hospital,Yiyang,Hunan,China,413099[7]The Affiliated Hospital of Qingdao University,Qingdao,Shandong,China,266057[8]Affiliated Hospital of Southwest Medical University,Luzhou,Sichuan,China,646000
研究目的：
The main aim of this clinical trial is to assess the safety and tolerability of PN20 in adult patients with chemotherapy-induced thrombocytopenia (CID). The main questions it aims to answer are: - Is PN20 safe in these patients? - Could these patients potentially benefit from PN20 prevention? Participants will - Receive subcutaneous injections of PN20 according to weight on the first day of chemotherapy cycle, within 1 hour before the administration of chemotherapy drugs, - Visit the clinic on Day 1 (D1), D2, D3, D4, D5, D8, D11, D13, D15 and D21 for assessment.
